Dec. 18, 2024
by Andrii Buvailo, PhD
News
After securing $40 million in August 2024, Noetik—an AI-native biotechnology company—announced in a recently released technical report the launch of …
Dec. 18, 2024
by Roman Kasianov
News
insitro has secured $25 million in milestone payments from Bristol Myers Squibb for reaching discovery milestones and identifying the first …
Dec. 18, 2024
by BiopharmaTrend
News
Sanofi has opened pre-proposal submissions for its 2025 iNext Awards, a pioneering program aimed at advancing high-risk, high-reward innovations in …
Dec. 17, 2024
by Roman Kasianov
News
Gameto, a biotechnology company focused on fertility treatments, announced the world’s first live birth using Fertilo, its ovarian support cell …
Dec. 17, 2024
by Nikhil Pradhan
Biopharma insight
Just in time for 2025 prediction season, a survey of the emerging AI drug discovery landscape, prepared by Chris Bradbury, …
Dec. 17, 2024
by Illia Petrov
News
Just two months after raising $120 million to advance its AI-driven tNova platform and internal immunology programs, Terray Therapeutics has …
Dec. 16, 2024
by BiopharmaTrend
News
A recent study by researchers at Chung-Ang University, South Korea, published in Nature Communications, reveals how a specific transfer RNA-derived …
Dec. 16, 2024
by Roman Kasianov
News
After debuting with 370$ million capital raise in September 2024, Candid Therapeutics, a San Diego-based biotechnology company specializing in T-cell …
Dec. 16, 2024
by BiopharmaTrend
News
The Royal Society for the Prevention of Accidents (RoSPA) is urging the public to take extra precautions during the festive …
Dec. 13, 2024
by Roman Kasianov
News
BeiGene, Ltd. (NASDAQ: BGNE), a global oncology company soon to be renamed BeOne Medicines Ltd., has announced a global licensing …
Dec. 13, 2024
by BiopharmaTrend
News
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company, has announced preclinical Proof-of-Concept (PoC) results for a precision cancer vaccine …
Dec. 12, 2024
by BiopharmaTrend
News
Elevation Oncology has entered into a licensing agreement with Synaffix B.V., a Lonza company, to access its antibody-drug conjugate (ADC) …